Physician profile
Ronald Myint
NPI 1003076795
$18,034.86
in general payments reported to CMS, 2019-2025
76 companies · $4,234 in 2025
The $4,234 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,921 · 2020: $520 · 2021: $1,109 · 2022: $1,305 · 2023: $1,279 · 2024: $1,668 · 2025: $4,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,081 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,080.72 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,913.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,463.50 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Merck Sharp & Dohme LLC | $862.26 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $815.31 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Celgene Corporation | $663.32 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $632.12 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Genentech USA, INC. | $567.21 | 2019-2025 | Tecentriq Hybreza, Venclexta, Polivy |
| Pfizer INC. | $498.06 | 2019-2025 | |
| Lilly USA, LLC | $399.15 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $392.08 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Eisai INC. | $361.99 | 2019-2025 | |
| Genzyme Corporation | $342.24 | 2019-2025 | |
| Daiichi Sankyo INC. | $276.14 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Incyte Corporation | $273.31 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Ipsen Biopharmaceuticals, INC | $260.23 | 2019-2025 | Onivyde |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Myint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.